Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i><scp>ARNT</scp></i>/<scp>HIF</scp>‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma

21 Jun 2018

Abstract excerpt

1q21 gain is a common cytogenetic abnormality featuring high-risk multiple myeloma (HRMM). However, the molecular mechanism underlying the adverse prognostic effect of 1q21 gain remains largely unclear. Here, we report that ARNT/HIF-1β, a 1q21 gene, is highly expressed in HRMM and induced by microenvironmental hypoxia, which confers drug resistance and correlates with inferior outcome. Analysis of the gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29926531
DOI: 10.1002/cam4.1596

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i><scp>ARNT</scp></i>/<scp>HIF</scp>‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myelomaPMID 29926531Read ↗

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic TargetsSemantic proximity Read ↗

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsSemantic proximity Read ↗

Hypoxia–Immune-Related Gene SLC19A1 Serves as a Potential Biomarker for Prognosis in Multiple MyelomaSemantic proximity Read ↗

Impact of hypoxia on the pathogenesis and therapy resistance in multiple myelomaSemantic proximity Read ↗

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomicsSemantic proximity Read ↗

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.Semantic proximity Read ↗

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity Read ↗

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read ↗

<em>KRAS/NRAS</em> Mutation-Associated Transcriptional Dysregulation Identifies <em>NRL</em>, <em>CREM </em>and <em>IL-6</em> as Candidate Prognostic Biomarkers in Multiple MyelomaSemantic proximity Read ↗

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.Semantic proximity Read ↗

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Chemogenomics Mapping of Potential Drugs and Targets for Treatment of Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.